<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04636814</url>
  </required_header>
  <id_info>
    <org_study_id>CLI-06001AA1-05</org_study_id>
    <nct_id>NCT04636814</nct_id>
  </id_info>
  <brief_title>A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)</brief_title>
  <acronym>PILLAR</acronym>
  <official_title>A 52-week, Randomized, Double-blind, Double-dummy, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg), Parallel Group, Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI add-on to Maintenance Triple Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and the safety of two doses of CHF6001&#xD;
      (Tanimilast) as add-on to maintenance triple therapy in the target patient population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 12, 2021</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of moderate and severe exacerbations occurring during the planned 52-week treatment period.</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>Moderate or severe exacerbation is defined by symptomatic worsening of COPD:&#xD;
Moderate : requiring use of systemic corticosteroids (oral/IV/IM corticosteroids), and/or use of antibiotics&#xD;
Severe : requiring hospitalisation or resulting in death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The time to first moderate or severe exacerbation.</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The annual rate of severe exacerbations.</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to first severe exacerbation.</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of all on-treatment severe exacerbations.</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of all on-treatment exacerbations requiring systemic corticosteroids.</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline (pre-dose Visit 2) in pre-dose FEV1, at week 52.</measure>
    <time_frame>At week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in SGRQ total and domain scores at week 52.</measure>
    <time_frame>At week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SGRQ response (change from baseline SGRQ total score ≤ -4) at week 52.</measure>
    <time_frame>At week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to last inter-visit period (week 40-52) in E-RS Total and subscale scores.</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>E-RS response (change from baseline E-RS Total score ≤ -2) at week 52.</measure>
    <time_frame>At week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to last inter-visit period (week 40-52) in the percentage of days without intake of rescue medication and in the average rescue medication use (number of puffs).</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to study medication discontinuation for any reason.</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to moderate or severe exacerbation or study medication discontinuation due to any adverse event, lack of efficacy or death (composite endpoint) and time to study medication discontinuation component.</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to moderate/severe exacerbation or study medication discontinuation due to any class-related AE, lack of efficacy, or death (composite endpoint) and time to study medication discontinuation component.</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">3980</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>CHF6001 1600µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CHF6001 3200µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Roflumilast</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF6001 1600µg</intervention_name>
    <description>CHF6001 400µg, 2 inhalations bid (total daily dose of 1600µg) and Roflumilast matching placebo, 1 tablet once daily</description>
    <arm_group_label>CHF6001 1600µg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF6001 3200µg</intervention_name>
    <description>CHF6001 800µg, 2 inhalations bid (total daily dose of 3200µg) and Roflumilast matching placebo, 1 tablet once daily</description>
    <arm_group_label>CHF6001 3200µg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>CHF6001 matching placebo, 2 inhalations bid and Roflumilast matching placebo, 1 tablet once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Roflumilast</intervention_name>
    <description>- 1 tablet of Roflumilast (Daliresp®), 250µg, once daily during the first 4 weeks of treatment then 1 tablet of Roflumilast (Daliresp®), 500µg, once daily for the remaining treatment period and CHF6001 matching placebo, 2 inhalations bid</description>
    <arm_group_label>Roflumilast</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults aged ≥ 40 years, with COPD and with chronic bronchitis.&#xD;
&#xD;
          -  Current smokers or ex-smokers (history of ≥10 pack years).&#xD;
&#xD;
          -  Post-bronchodilator FEV1 &lt;50% of the patient predicted normal value and FEV1/FVC ratio&#xD;
             &lt; 0.7.&#xD;
&#xD;
          -  At least, one moderate or severe COPD exacerbation in the previous year.&#xD;
&#xD;
          -  CAT score &gt;10.&#xD;
&#xD;
          -  Subjects on regular maintenance triple therapy for at least 12 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with current asthma.&#xD;
&#xD;
          -  Subjects with moderate or severe COPD exacerbation 4 weeks before study entry and&#xD;
             randomisation&#xD;
&#xD;
          -  Subjects with known α-1 antitrypsin deficiency as the underlying cause of COPD.&#xD;
&#xD;
          -  Subjects with COPD emphysema or mixed phenotypes.&#xD;
&#xD;
          -  Subjects with known respiratory disorders other than COPD.&#xD;
&#xD;
          -  Subjects with lung volume reduction surgery.&#xD;
&#xD;
          -  Subjects with active cancer or a history of lung cancer.&#xD;
&#xD;
          -  Subjects under Roflumilast treatment within 6 months before study entry.&#xD;
&#xD;
          -  Subjects with a diagnosis of depression, generalised anxiety disorder, suicidal&#xD;
             ideation.&#xD;
&#xD;
          -  Subjects with clinically significant cardiovascular condition.&#xD;
&#xD;
          -  Subjects with neurological disease.&#xD;
&#xD;
          -  Subjects with clinically significant laboratory abnormalities.&#xD;
&#xD;
          -  Subjects with moderate or severe hepatic impairment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernando J. MARTINEZ, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Cornell Medical College, New York Presbyterian Hospital, 1305 York avenue box 96 New York 10021 USA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chiesi Clinical Trial info</last_name>
    <phone>+ 39 0521 279 715</phone>
    <email>clinicaltrials_info@chiesi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Site 100524 - Medical Centre New Rehabilitation Centre EOOD</name>
      <address>
        <city>Stara Zagora</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dimo Dimov</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Bulgaria</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 16, 2020</study_first_submitted>
  <study_first_submitted_qc>November 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2020</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>chronic bronchitis</keyword>
  <keyword>PDE4 inhibitor</keyword>
  <keyword>anti-inflammatory respiratory drug</keyword>
  <keyword>Tanimilast</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchitis</mesh_term>
    <mesh_term>Bronchitis, Chronic</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

